Veradermics Balance Sheet
NYSE: MANEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Veradermics financial position
At the end of fiscal 2025, Veradermics reported total assets of $152.6 million, up 174.8% from a year earlier against total liabilities of $9.2 million. Shareholders' equity was negative at -$121.0 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $21.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 16.66, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Veradermics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 |
|---|---|---|
| Cash & Equivalents | 21.77M | 53.08M |
| Short-Term Investments | 120.10M | 0 |
| Total Current Assets | 152.49M | 55.53M |
| Property, Plant & Equipment | 22.00K | 0 |
| Total Assets | 152.62M | 55.53M |
| Accounts Payable | 2.13M | 2.25M |
| Total Current Liabilities | 9.15M | 4.72M |
| Total Liabilities | 9.16M | 4.72M |
| Shareholders' Equity | -121.01M | -48.48M |
| Retained Earnings | -123.42M | -49.23M |
| Net Cash (Debt) | 141.86M | 53.08M |
| Shares Outstanding | 749.76K | 736.93K |
This table shows 2 annual periods of Veradermics's balance sheet, from FY 2025 back to FY 2024, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow MANE's reporting calendar. What is a balance sheet?